![Arndt Vogel (@arndtvogel) 's Twitter Profile](https://pbs.twimg.com/profile_images/1539706083576631296/9rqRL-CM_200x200.jpg)
Arndt Vogel
@arndtvogel
Clinician-scientist, focused on liver cancer & precision oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
ID: 1211086357
23-02-2013 08:40:33
1,1K Tweet
6,6K Followers
440 Following
![Arndt Vogel (@arndtvogel) 's Twitter Profile Photo Arndt Vogel (@arndtvogel) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1539706083576631296/9rqRL-CM_200x200.jpg)
New targets in immunotherapy beyond CTL4 and PD(L)1 - New targets and new drugs #EMSOGI24 👉Overcoming multiple resistance mechanisms to ICI 👉finding new ways to enhance immune responses 👉🎯: IL-2, LAG-3, TIM-3, TIGIT, B7-H3, CD137... #ESMOAmbassadors ESMO - Eur. Oncology
![Arndt Vogel (@arndtvogel) on Twitter photo New targets in immunotherapy beyond CTL4 and PD(L)1 - New targets and new drugs
#EMSOGI24
👉Overcoming multiple resistance mechanisms to ICI
👉finding new ways to enhance immune responses
👉🎯: IL-2, LAG-3, TIM-3, TIGIT, B7-H3, CD137...
#ESMOAmbassadors <a href="/myESMO/">ESMO - Eur. Oncology</a> New targets in immunotherapy beyond CTL4 and PD(L)1 - New targets and new drugs
#EMSOGI24
👉Overcoming multiple resistance mechanisms to ICI
👉finding new ways to enhance immune responses
👉🎯: IL-2, LAG-3, TIM-3, TIGIT, B7-H3, CD137...
#ESMOAmbassadors <a href="/myESMO/">ESMO - Eur. Oncology</a>](https://pbs.twimg.com/media/GRKWqoiX0AAT_Nd.jpg)